Table 1 Characteristics of studies inclcuded in the meta-analysis
From: The impact of triglyceride-glucose index on ischemic stroke: a systematic review and meta-analysis
Study | Country | Study design | Male% | Age (mean ± sd) | Study time | Participants | TyG index condition | Type of outcome |
|---|---|---|---|---|---|---|---|---|
The association of TyG index with risk of ischemic stroke | ||||||||
Wenrui S 2019 | China | cross-sectional | 40.20% | 59.95 ± 10.07 | 8 M | 10,900 from rural areas of northeast China | TyG I | IS Incidence |
Anxin Wang 2021 | China | prospective cohort | 79.62% | 51.38 ± 11.45 | 11.02 Y | 97,653 from the Kailuan community in Tangshan City, China | TyG I | IS Incidence |
Yang Zhao 2021 | China | prospective cohort | 40.88% | 53.93 ± 11.19 | 6 Y | 11,777 from the Rural Chinese Cohort Study | TyG I | IS Incidence |
Qian Liu 2022 | China | prospective cohort | 79.61% | 51.49 ± 12.53 | 10.33 Y | 96,541 from the Kailuan community in Tangshan City, China | TyG I | IS Incidence |
Qi Zhao 2021 | China | retrospective cohort | 73.70% | 59.70 ± 9.30 | 4 Y | 1510 individuals diagnosed with NSTE-ACS | TyG II | IS Incidence |
Shucheng Si 2021 | European | prospective cohort | 43.01% | 56.00 ± 8.02 | 4 Y | 273,368 from the UK Biobank cohort | TyG I | IS Incidence |
Longlong Hu 2022 | China | prospective cohort | 52.76% | 68.77 ± 6.19 | 1.72 Ys | 8487 from the China H-type Hypertension Registry Study | TyG I | IS Incidence |
Xianxuan Wang 2022 | China | prospective cohort | 76.08% | 49.03 ± 11.84 | 9 Y | 54,098 from the Kailuan community in Tangshan City, China | TyG I | IS Incidence |
The association of TyG index with prognosis among patients with ischemic stroke | ||||||||
Yimo Zhou 2020 | China | cohort | 63.48% | 64.83 ± 11.90 | 1 Y | 16,310 from the China National Stroke Registry II | TyG I | Stroke recurrence, All-cause mortality, Poor functional outcome, Neurologic worsening |
Bingjun Zhang 2020 | China | retrospective observational | 51.60% | 66.30 ± 14.20 | 2 Y | 4570 from the eICU Collaborative Research Database (208 United States hospitals) | TyG I | All-cause mortality |
Minwoo Lee 2021 | Korea | retrospective observational | 59.00% | 69.50 ± 12.40 | 4 Y | 183 patients from three university-affiliated hospitals | TyG II | Poor functional outcome |
Ki-Woong N (a) 2021 | Korea | retrospective cross-sectional | 59.30% | 69.04 ± 11.24 | 4 Y | 305 from the Seoul National University Hospital | TyG IV | Neurologic worsening |
Zongyi Hou 2021 | China | prospective cohort | 63.30% | 64.83 ± 12.20 | 1 Y | 12,964 from the China National Stroke Registry II | TyG I | Stroke recurrence, Poor functional outcome, All-cause mortality |
Ki-Woong N (b) 2021 | Korea | retrospective cross-sectional | 58.52% | 72.03 ± 5.60 | 7 Y | 176 from the Seoul National University Boramae Medical Center | TyG III | Stroke recurrence |
Xiaomeng Yang 2022 | China | cohort | 62.97% | 62.66 ± 14.60 | 1 Y | 1226 from the Abnormal Glucose Regulation in Patients with Acute Stroke across China registry | TyG I | Stroke recurrence, All-cause mortality |
Sheng-Feng Lin 2022 | China | multicenter prospective cohort | 63.68% | 69.09 ± 12.23 | 12 Y | 914 clinical data from 30 hospitals in Taiwan were collected and registered in the TTT-AIS registry | TyG III | Poor functional outcome, All-cause mortality |
Emma M. S.Toh 2022 | Singapore | retrospective cohort | 61.50% | 65.35 ± 15.60 | 11.75 Y | 698 from a comprehensive stroke center | TyG II | All-cause mortality, Poor functional outcome |
Fang Wang 2022 | China | retrospective cohort | 67.20% | 70.70 ± 5.94 | 1 Y | 955 from the Nanjing Stroke Registry Program | TyG I | Stroke recurrence |